Oncology Institute’s (TOI) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Oncology Institute (NASDAQ:TOI) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock.

TOI has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, January 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price target on shares of Oncology Institute in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Oncology Institute Price Performance

TOI opened at $2.76 on Monday. Oncology Institute has a 12 month low of $0.63 and a 12 month high of $4.88. The business has a 50-day moving average of $3.04 and a two-hundred day moving average of $3.40. The stock has a market capitalization of $271.53 million, a price-to-earnings ratio of -4.31 and a beta of 0.14.

Insider Activity at Oncology Institute

In other news, Director Brad Hively sold 13,333 shares of Oncology Institute stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the transaction, the director directly owned 683,721 shares of the company’s stock, valued at $2,577,628.17. The trade was a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 8.50% of the stock is currently owned by company insiders.

Institutional Trading of Oncology Institute

A number of institutional investors and hedge funds have recently bought and sold shares of the business. LPL Financial LLC lifted its position in Oncology Institute by 1.5% during the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock valued at $964,000 after buying an additional 3,900 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Oncology Institute by 9.1% during the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock valued at $171,000 after acquiring an additional 4,007 shares in the last quarter. HighTower Advisors LLC boosted its position in Oncology Institute by 5.5% during the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock worth $306,000 after purchasing an additional 4,489 shares during the period. Cetera Investment Advisers boosted its position in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the period. Finally, Larson Financial Group LLC raised its position in Oncology Institute by 19.7% in the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company’s stock valued at $112,000 after purchasing an additional 5,181 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.